Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow. The company also offers Neurolite, an injectable that is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures that assess blood flow distribution to the heart. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LNTH
CUSIPN/A
Phone978-671-8001
Debt
Debt-to-Equity Ratio7.87
Current Ratio3.51
Quick Ratio2.80
Price-To-Earnings
Trailing P/E Ratio13.65
Forward P/E Ratio15.81
P/E Growth1.34
Sales & Book Value
Annual Sales$331.38 million
Price / Sales1.57
Cash Flow$1.5723 per share
Price / Cash8.65
Book Value$0.62 per share
Price / Book21.94
Profitability
EPS (Most Recent Fiscal Year)$1.00
Net Income$123.38 million
Net Margins38.32%
Return on Equity-145.14%
Return on Assets11.84%
Miscellaneous
Employees483
Outstanding Shares38,280,000
Market Cap$524.45
Lantheus (NASDAQ:LNTH) Frequently Asked Questions
What is Lantheus' stock symbol?
Lantheus trades on the NASDAQ under the ticker symbol "LNTH."
How were Lantheus' earnings last quarter?
Lantheus Holdings Inc (NASDAQ:LNTH) released its quarterly earnings results on Wednesday, May, 2nd. The medical equipment provider reported $0.22 EPS for the quarter, meeting the consensus estimate of $0.22. The medical equipment provider earned $82.63 million during the quarter, compared to the consensus estimate of $81.15 million. Lantheus had a net margin of 38.32% and a negative return on equity of 145.14%. Lantheus's revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.11 EPS. View Lantheus' Earnings History.
What price target have analysts set for LNTH?
3 brokerages have issued 12-month price targets for Lantheus' shares. Their predictions range from $23.00 to $27.00. On average, they anticipate Lantheus' share price to reach $25.00 in the next twelve months. This suggests a possible upside of 83.8% from the stock's current price. View Analyst Ratings for Lantheus.
What is the consensus analysts' recommendation for Lantheus?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Lantheus' key competitors?
Some companies that are related to Lantheus include Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Vermillion (VRML), ImmuCell (ICCC), Akers Biosciences (AKER), Achieve Life Sciences (ACHV), Arca Biopharma (ABIO), GeneNews (GNWSF) and Fluoropharma Medical (FPMI).
Who are Lantheus' key executives?
Lantheus' management team includes the folowing people:
- Ms. Mary Anne Heino, CEO, Pres & Director (Age 58)
- Mr. John W. Crowley, CFO & Treasurer (Age 54)
- Mr. Michael P. Duffy, Sr. VP of Strategy & Bus. Devel., Gen. Counsel and Sec. (Age 57)
- Mr. Timothy G. Healey, Sr. VP of Commercial (Age 52)
- Mr. William C. Dawes Jr., VP of Manufacturing and Operations (Age 46)
When did Lantheus IPO?
(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.
Has Lantheus been receiving favorable news coverage?
News coverage about LNTH stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Lantheus earned a news sentiment score of 0.14 on Accern's scale. They also assigned news headlines about the medical equipment provider an impact score of 45.86 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Lantheus' major shareholders?
Lantheus' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (1.51%), Bank of Montreal Can (0.44%), Fisher Asset Management LLC (0.26%), James Investment Research Inc. (0.23%) and Municipal Employees Retirement System of Michigan (0.19%). Company insiders that own Lantheus stock include Avista Capital Partners Gp, Ll, Cesare Orlandi, David F Burgstahler, Derace L Schaffer, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy and Timothy G Healey. View Institutional Ownership Trends for Lantheus.
Which institutional investors are selling Lantheus stock?
LNTH stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Fisher Asset Management LLC and Municipal Employees Retirement System of Michigan. Company insiders that have sold Lantheus company stock in the last year include Avista Capital Partners Gp, Ll, Cesare Orlandi, David F Burgstahler, Derace L Schaffer, John W Crowley, Julie Mchugh, Michael P Duffy and Timothy G Healey. View Insider Buying and Selling for Lantheus.
Which institutional investors are buying Lantheus stock?
How do I buy shares of Lantheus?
Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lantheus' stock price today?
One share of LNTH stock can currently be purchased for approximately $13.60.
How big of a company is Lantheus?
Lantheus has a market capitalization of $524.45 million and generates $331.38 million in revenue each year. The medical equipment provider earns $123.38 million in net income (profit) each year or $1.00 on an earnings per share basis. Lantheus employs 483 workers across the globe.
How can I contact Lantheus?
Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]
MarketBeat Community Rating for Lantheus (NASDAQ LNTH)
MarketBeat's community ratings are surveys of what our community members think about Lantheus and other stocks. Vote "Outperform" if you believe LNTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LNTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
